Eagle Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Eagle Pharmaceuticals

07/03/2022 14:33

* Eagle Pharmaceuticals Inc  EGRX.OQ  reported quarterly
adjusted
earnings of 85 cents​​ per share for the quarter ended in
December. The mean expectation of three analysts for the quarter
was for earnings of 94 cents per share.
    * Revenue fell 15.2% to $42.32 million from a year ago; 
analysts
expected $51.08 million. 
    * Eagle Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 48 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Eagle Pharmaceuticals Inc shares had fallen by 11.4% this
quarter.
    * The company reported a quarterly loss of $6.2 million.
    * Wall Street's median 12-month price target for Eagle
Pharmaceuticals Inc is $50.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 7 at 02:33 p.m.  ​All
figures in US dollars unless otherwise stated